Have any questions? Contact us.

+1 (888) 560-2073
23Oct 2015
Oct 23, 2015

Development of an LC/MS-MS Naloxone Hydrolysis Assay

ABSTRACT OVERVIEW

Naloxone is a synthetic narcotic that acts as an opioid antagonist countering the effect of opioid overdose. It is also co-formulated with buprenorphine (Suboxone®, Zubsolv®, Bunavail™ buccal film) to prevent misuse and to produce withdrawal symptoms if the combination formulation is altered or naloxone is administered parenterally. A pain medication monitoring laboratory evaluated IMCSzyme®, a genetically modified β-glucuronidase, hydrolysis efficiency for the naloxone assay, which deconjugates the major urinary metabolites of naloxone, nornaloxone (noroxymorphone), and 6β-naloxol. The study reported ~70% hydrolysis efficiency at 65 °C for 60 minutes, with satisfactory precision and reproducibility.

IMCSzyme was a satisfactory choice for naloxone hydrolysis assay. Naloxone glucuronide is the most prevalent metabolite in urine relative to the other metabolites monitored. Application to patient sample analysis was 100% successful in detecting positivity of naloxone in all of the Suboxone patient samples tested.

Download Technical Note

This information was summarized by IMCS from the technical poster “Development of an LC/MS-MS Naloxone Hydrolysis Assay Using a Recombinant Beta-Glucuronidase for Urinalysis” presented by Ameritox, Ltd. at SOFT 2015

Comments are closed.